恒瑞医药揽下大单，医疗创新ETF(516820.SH)强势拉升，现涨0.98%

Group 1 - The medical innovation ETF (516820.SH) experienced a strong increase of 0.98%, with constituent stocks such as BaiLi Tianheng (688506) rising by 3.87%, HengRui Medicine (600276) by 3.38%, and XinChuang (300832) by 2.87% [1] - HengRui Medicine has reached an agreement with Glenmark Specialty, granting Glenmark exclusive rights to develop and commercialize the drug Rukang Trastuzumab in all global regions except for China, Hong Kong, Macau, Taiwan, the USA, Canada, and Europe [1] - The innovative drug sector is expected to maintain its favorable outlook, with continuous policy support and enhanced global competitiveness for Chinese innovative drugs, leading to sustained commercial profitability [1] Group 2 - Institutions remain confident in high-quality innovation and the innovation industry chain, viewing any short-term disturbances as buying opportunities, especially with the anticipated increase in US interest rates which will enhance global liquidity and the trend of technology stocks [2] - Investors who missed the initial rally in the pharmaceutical sector can consider the medical innovation ETF (516820) as a means to capitalize on the rebound of core pharmaceutical assets [2]